Aplastic anemia
MONDO:0015909Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.
418 clinical trials for this condition and its sub-types, 110 tagged with Aplastic anemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Aplastic anemia
-
Acquired aplastic anemia 38 trials · 303 incl. sub-types
3 sub-types
- Primary myelofibrosis 191 trials · 195 incl. sub-types Sub-types →
- Paroxysmal nocturnal hemoglobinuria 73 trials Sub-types →
- Primary acquired red cell aplasia 0 trials · 2 incl. sub-types Sub-types →
-
Inherited aplastic anemia 2 trials · 53 incl. sub-types
5 sub-types
- Fanconi anemia 29 trials · 42 incl. sub-types Sub-types →
- Diamond-Blackfan anemia 17 trials Sub-types →
- WT limb-blood syndrome 0 trials
- Autosomal dominant aplasia and myelodysplasia 0 trials
- Pancytopenia-developmental delay syndrome 0 trials
-
Idiopathic aplastic anemia 9 trials
-
Myelophthisic anemia 0 trials
Most studied deeper sub-types
-
New cord blood matching method could expand transplant access for blood cancer patients
Disease control CompletedThis study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a drug revive blood cell production in children with aplastic anemia?
Disease control CompletedThis phase II trial is investigating whether eltrombopag, a drug that stimulates platelet production, can help children with severe aplastic anemia when combined with standard immunosuppressive therapy. The study will enroll children with newly diagnosed, relapsed, or refractory …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare blood disorder: experimental pill reduces need for transfusions
Disease control CompletedThis study tested a drug called bitopertin in 15 adults with Diamond-Blackfan anemia (DBA), a rare inherited condition that causes severe anemia. Participants took the pill daily for 8 months, with doses possibly increasing over time. The goal was to see if the drug could raise h…
Phase 1/2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Hormone drug may slow Aging-Related diseases in rare condition
Disease control CompletedThis study tested whether low doses of the hormone drug danazol can slow the shortening of telomeres—the protective caps on DNA—in people with telomere diseases. These conditions can cause bone marrow failure, lung scarring, and liver damage. Eighteen participants took danazol fo…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Rabbit antibodies show promise for rare bone marrow disease
Disease control CompletedThis phase 2 trial tested a combination of rabbit antithymocyte globulin (Thymoglobuline) and ciclosporin in 35 people with acquired aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal was to see if this rabbit-based immune-suppressing tre…
Phase 2 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo shows promise for rare bone marrow failure
Disease control CompletedThis study tested whether adding eltrombopag to standard immunosuppressive therapy improves early recovery in patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. 202 participants received either standard treatment (horse a…
Phase 3 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a daily pill boost blood counts in aplastic anemia?
Disease control CompletedThis study tested the drug eltrombopag in 34 people with moderate aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. Eltrombopag is a pill that mimics a natural protein to stimulate blood cell production. Researchers measured whether it safely imp…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Personalized plans boost survival odds for older stem cell patients
Disease control CompletedThis study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New transplant approach shows promise for rare blood disorder
Disease control CompletedThis study tested a stem cell transplant from a half-matched family donor for people with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal was to see if this approach could improve survival one year after the transplant. The tria…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
One donor, two transplants: could this end lifelong Anti-Rejection drugs?
Disease control CompletedThis pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo treatment shows promise for kids with rare bone marrow failure
Disease control CompletedThis study reviewed medical records of 13 Korean children with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. Researchers wanted to see if adding eltrombopag to standard immunosuppressive therapy was safe and effective. Over 6 months, t…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New 9-Day combo shows promise for rare bone marrow disease
Disease control CompletedThis study tested a new 9-day treatment plan for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The treatment combines three drugs (rabbit antithymocyte globulin, cyclosporine, and levamisole) to suppress the immune sys…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo shows promise for rare blood disorder
Disease control CompletedThis study tested whether adding eltrombopag (a platelet booster) to standard immune-suppressing drugs (r-ATG and cyclosporine A) helps patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. Thirty-six East-Asian adults and c…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Lower chemo dose may prevent transplant complications
Disease control CompletedThis study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood dis…
Phase 2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for tough anemia: drug boosts blood cells in failed cases
Disease control CompletedThis study tested a drug called eltrombopag in 20 Chinese adults with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. Participants had not responded to previous treatments. The drug was given daily for up to a year to see if it could imp…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New transplant recipe may tame severe anemia
Disease control CompletedThis study reviews a modified transplant conditioning regimen for severe aplastic anemia in 72 patients across two hospitals. The approach uses a combination of fludarabine, melphalan, and cyclophosphamide to prepare the body for a stem cell transplant. Researchers looked at how …
Sponsor: Hematology department of the 920th hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug combo shows promise for rare blood disorder
Disease control CompletedThis phase 2 trial tested whether adding luspatercept to standard cyclosporine treatment helps people with non-severe aplastic anemia. The study enrolled 58 newly diagnosed adults who had low blood counts but did not yet need transfusions. The goal was to see if the combination c…
Phase 2 • Sponsor: Bing Han • Aim: Disease control
Last updated Jun 26, 2026 17:44 UTC
-
Ancient heat therapy tested to prevent post-transplant bladder pain
Prevention CompletedThis study tests whether moxibustion, a traditional therapy that burns herbs near the skin, can prevent hemorrhagic cystitis (painful bladder inflammation) in 266 patients receiving stem cell transplants. Participants are randomly assigned to receive either standard care or stand…
Sponsor: Yi Zhang • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Could a platelet-boosting drug shorten recovery after stem cell transplants?
Knowledge-focused CompletedThis study looks back at medical records of people who had an allogeneic stem cell transplant to see whether romiplostim helped their platelets recover faster. Platelets are blood cells that help clotting, and low counts are common after transplant. The researchers will compare p…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
No treatment, just observation: large study looks at PNH blood cells
Knowledge-focused CompletedThis completed study looked at red and white blood cells in people with a rare blood disorder called PNH who also have bone marrow failure. Over 5,500 participants aged 10 and older with aplastic anemia or related conditions provided blood samples. The goal was simply to learn mo…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New registry aims to unravel severe blood disorders in youth
Knowledge-focused CompletedThis completed registry study followed 80 children and young adults with severe immune cytopenias, including immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndrome. Researchers observed participants over up to 4 years to improve diagnosis and track the disease c…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC